<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596866</url>
  </required_header>
  <id_info>
    <org_study_id>Brigatinib-3001</org_study_id>
    <secondary_id>2018-001957-29</secondary_id>
    <nct_id>NCT03596866</nct_id>
  </id_info>
  <brief_title>A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer</brief_title>
  <acronym>ALTA-3</acronym>
  <official_title>A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and&#xD;
      delivers a dose of chemotherapy directly to the tumor. In this study, participants will be&#xD;
      people with non-small-cell lung cancer (NSCLC for short). The main aim of the study is to&#xD;
      learn if brigatinib stops the tumors from growing, or if the tumors have shrunk or&#xD;
      disappeared, compared to a medicine called alectinib.&#xD;
&#xD;
      At the first visit, the study doctor will check who can take part. Participants who can take&#xD;
      part will be picked for 1 of 2 treatments by chance:&#xD;
&#xD;
        -  Brigatinib tablets&#xD;
&#xD;
        -  Alectinib capsules&#xD;
&#xD;
      All participants will take brigatinib or alectinib at about the same time every day. They&#xD;
      will continue with treatment throughout the study unless their cancer gets worse, they have&#xD;
      side effects from the treatment, they leave the study for certain reasons, or the study is&#xD;
      stopped.&#xD;
&#xD;
      After stopping treatment, participants will visit the study clinic for a check-up 30 days&#xD;
      later.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called brigatinib. Brigatinib has been demonstrated to&#xD;
      benefit people with ALK+ NSCLC.&#xD;
&#xD;
      The comparator drug is called alectinib. Alectinib has been demonstrated to benefit people&#xD;
      with ALK+ NSCLC. Both drugs belong to a class of drugs called anaplastic lymphoma kinase&#xD;
      (ALK) inhibitors. Both drugs are taken by mouth. Both drugs are approved by the United States&#xD;
      Food and Drug Administration (US FDA).&#xD;
&#xD;
      The study will enroll approximately 246 participants. Participants will be randomly assigned&#xD;
      (by chance, like flipping a coin) in 1:1 ratio to one of the two treatment groups:&#xD;
&#xD;
        -  Brigatinib&#xD;
&#xD;
        -  Alectinib&#xD;
&#xD;
      All participants will be asked to take brigatinib or alectinib at the same time each day&#xD;
      throughout the study.&#xD;
&#xD;
      This multi-center trial will be conducted in the United States, Argentina, Austria, Canada,&#xD;
      Chile, China, Croatia, France, Germany, Greece, Hong Kong, Italy, Mexico, Romania, Russia,&#xD;
      South Korea, Spain, Sweden, Taiwan, and Thailand. The overall time to participate in this&#xD;
      study is 5 years. Participants will make multiple visits to the clinic, and 30 days after&#xD;
      last dose of study drug for a follow-up assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2019</start_date>
  <completion_date type="Anticipated">May 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS as Assessed by Blinded Independent Review Committee (BIRC) per RECIST v1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>PFS is defined as the time interval from the date of randomization until the first date at which disease progression is objectively documented via RECIST v1.1 by BIRC, or death due to any cause, whichever occurs first, in the full analysis set. PFS will be censored for participants without documented disease progression or death at the last valid tumor response assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>OS is defined as the time interval from the date of randomization until death due to any cause in the full analysis set. It will be censored on the date of last contact for those participants who are alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS as Assessed by Investigator per RECIST v1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>PFS is defined as the time interval from the date of randomization until the first date at which disease progression is objectively documented via RECIST v1.1 by investigator, or death due to any cause, whichever occurs first, in the full analysis set. PFS will be censored for participants without documented disease progression or death at the last valid tumor response assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) as Assessed by Investigator and BIRC per RECIST v1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>ORR is defined as the percentage of the participants who are confirmed to have achieved complete response (CR) or partial response (PR), using RECIST v1.1 after the initiation of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as Assessed by Investigator and BIRC</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>DOR is defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that the progressive disease (PD) is objectively documented or death, as assessed by the investigator and BIRC, using RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response as Assessed by Investigator and BIRC</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Time to response is defined as the time interval from randomization until the initial observation of CR or PR, as assessed by the investigator and BIRC, using RECIST v1.1. Time to response will be summarized using descriptive statistics in participants with confirmed objective response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial Objective Response Rate (iORR) as Assessed by BIRC per Modified RECIST v1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>iORR, as assessed by the BIRC, is defined as the percentage of the participants who have achieved CR or PR in the central nervous system (CNS) per a modification RECIST v1.1 after the initiation of study treatment in participants with CNS metastases at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial Duration of Response (iDOR) as Assessed by the BIRC per Modified RECIST v1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>iDOR, as assessed by the BIRC per modified RECIST v1.1, is defined as the time interval from the time that the measurement criteria are first met for CR or PR in the CNS (whichever is first recorded) until the first date that the PD in the CNS is objectively documented or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Intracranial Disease Progression (iPD) as Assessed by BIRC per Modified RECIST v1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Time to iPD, as assessed by the BIRC, is defined as the time interval from the date of randomization until the first date at which iPD is objectively documented via a modification of RECIST v1.1. Time to iPD will be censored for participants without documented iPD at the last valid intracranial tumor response assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQOL) from European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 v3.0) Score</measure>
    <time_frame>First dose of study drug up to 30 days after last dose (approximately 5 years)</time_frame>
    <description>EORTC QLQ-C30 incorporates 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC QLQ-C30 contains 28 questions (4-point scale where 1=Not at all [best] to 4=Very Much [worst]) and 2 questions (7-point scale where 1=Very poor [worst] to 7= Excellent [best]). Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status scale, higher scores represent better quality of life (QOL); for the symptom scales, lower scores represent better QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL from EORTC QLQ- Lung Cancer (LC) 13</measure>
    <time_frame>First dose of study drug up to 30 days after last dose (approximately 5 years)</time_frame>
    <description>HRQOL scores will be assessed with European Organization for Research and Treatment (EORTC), its lung cancer module QLQ-LC13. QLQ-LC13 contains 13 questions assessing lung cancer-associated symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and use of pain medication. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>ALK+ Advanced NSCLC</condition>
  <arm_group>
    <arm_group_label>Brigatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brigatinib 90 milligram (mg), tablets, orally, once daily 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alectinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alectinib 600 mg, capsules, orally twice daily until objective disease progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brigatinib</intervention_name>
    <description>Brigatinib Tablets.</description>
    <arm_group_label>Brigatinib</arm_group_label>
    <other_name>Alunbrig</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alectinib</intervention_name>
    <description>Alectinib Capsules.</description>
    <arm_group_label>Alectinib</arm_group_label>
    <other_name>Alecensa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          2. Have histologically or cytologically confirmed stage IIIB (locally advanced or&#xD;
             recurrent) or stage IV NSCLC.&#xD;
&#xD;
          3. Must meet one of the following criteria:&#xD;
&#xD;
               -  Have documentation of ALK rearrangement by a positive result from the Vysis ALK&#xD;
                  Break-Apart fluorescence in situ hybridization (FISH) Probe Kit or the Ventana&#xD;
                  ALK (D5F3) CDx Assay or Foundation Medicine's FoundationOne CDx.&#xD;
&#xD;
               -  Have documented ALK rearrangement by a different test and be able to provide&#xD;
                  tumor sample to the central laboratory. (Note: central laboratory ALK&#xD;
                  rearrangement testing results are not required to be obtained before&#xD;
                  randomization).&#xD;
&#xD;
          4. Had PD while on crizotinib, as assessed by the investigator or treating physician.&#xD;
             (Note: crizotinib does not need to be the last therapy a participant received. The&#xD;
             participant may have received chemotherapy as his/her last therapy).&#xD;
&#xD;
          5. Treatment with crizotinib for at least 4 weeks before progression.&#xD;
&#xD;
          6. Have had no other ALK inhibitor other than crizotinib.&#xD;
&#xD;
          7. Have had no more than 2 prior regimens of systemic anticancer therapy (other than&#xD;
             crizotinib) in the locally advanced or metastatic setting. Note: a systemic anticancer&#xD;
             therapy regimen will be counted if it is administered for at least 1 complete cycle. A&#xD;
             new anticancer agent used as maintenance therapy will be counted as a new regimen.&#xD;
             Neoadjuvant or adjuvant systemic anticancer therapy will be counted as a prior regimen&#xD;
             if disease progression/recurrence occurred within 12 months upon completion of this&#xD;
             neoadjuvant or adjuvant therapy. (Systemic therapy followed by maintenance therapy&#xD;
             will be considered as one regimen if the maintenance therapy consists of a drug or&#xD;
             drugs that were used in the regimen that immediately preceded maintenance).&#xD;
&#xD;
          8. Have at least 1 measurable (that is, target) lesion per RECIST v1.1.&#xD;
&#xD;
          9. Have recovered from toxicities related to prior anticancer therapy to national cancer&#xD;
             institute common terminology criteria for adverse events (NCI CTCAE) v4.03 grade less&#xD;
             than or equal to (&lt;=)1. (Note: treatment-related alopecia or peripheral neuropathy&#xD;
             that are grade greater than (&gt;) 1 are allowed, if deemed irreversible).&#xD;
&#xD;
         10. Have adequate organ function, as determined by:&#xD;
&#xD;
               -  Total bilirubin &lt;=1.5 times the upper limit of normal (ULN).&#xD;
&#xD;
               -  Estimated glomerular filtration rate greater than equal to (&gt;=) 30 milliliter per&#xD;
                  minute (mL/min)/1.73 square meter [m^2], using the modification of diet in renal&#xD;
                  disease equation.&#xD;
&#xD;
               -  Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) &lt;=2.5*ULN;&#xD;
                  &lt;=5*ULN is acceptable if liver metastases are present.&#xD;
&#xD;
               -  Serum lipase &lt;=1.5*ULN.&#xD;
&#xD;
               -  Platelet count &gt;=75*10^9 per liter [/L].&#xD;
&#xD;
               -  Hemoglobin &gt;=9 gram per deciliter (g/dL).&#xD;
&#xD;
               -  Absolute neutrophil count &gt;=1.5*10^9 / L.&#xD;
&#xD;
         11. Suitable venous access for study-required blood sampling (that is, including&#xD;
             pharmacokinetic [PK] and laboratory safety tests).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had participated in the control (crizotinib) arm of Study AP26113-13-301 (ALTA 1L).&#xD;
&#xD;
          2. Had received crizotinib within 7 days before randomization.&#xD;
&#xD;
          3. Have a history or presence at baseline of pulmonary interstitial disease, drug related&#xD;
             pneumonitis, or radiation pneumonitis.&#xD;
&#xD;
          4. Have uncontrolled hypertension. Participants with hypertension should be under&#xD;
             treatment for control of blood pressure upon study entry.&#xD;
&#xD;
          5. Had received systemic treatment with strong cytochrome P-450 (CYP) 3A inhibitors,&#xD;
             moderate CYP3A inhibitors, strong CYP3A inducers, or moderate CYP3A inducers within 14&#xD;
             days before randomization.&#xD;
&#xD;
          6. Treatment with any investigational systemic anticancer agents within 14 days or 5&#xD;
             half-lives, whichever is longer, before randomization.&#xD;
&#xD;
          7. Have been diagnosed with another primary malignancy other than NSCLC, except for&#xD;
             adequately treated nonmelanoma skin cancer or cervical cancer in situ; definitively&#xD;
             treated nonmetastatic prostate cancer; or patients with another primary malignancy who&#xD;
             are definitively relapse-free with at least 3 years elapsed since the diagnosis of the&#xD;
             other primary malignancy.&#xD;
&#xD;
          8. Had received chemotherapy or radiation therapy within 14 days before randomization&#xD;
             except for stereotactic radiosurgery (SRS) or stereotactic body radiation therapy.&#xD;
&#xD;
          9. Had received antineoplastic monoclonal antibodies within 30 days of randomization.&#xD;
&#xD;
         10. Had major surgery within 30 days of randomization. Minor surgical procedures, such as&#xD;
             catheter placement or minimally invasive biopsies, are allowed.&#xD;
&#xD;
         11. Have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening&#xD;
             (participants with asymptomatic brain metastases or participants who have stable&#xD;
             symptoms and did not require an increased dose of corticosteroids to control symptoms&#xD;
             within 7 days before randomization will be enrolled). Note: If a participant has&#xD;
             worsening neurological symptoms or signs due to CNS metastasis, the participant needs&#xD;
             to complete local therapy and be neurologically stable (with no requirement for an&#xD;
             increasing dose of corticosteroids or use of anticonvulsants) for 7 days before&#xD;
             randomization.&#xD;
&#xD;
         12. Have current spinal cord compression (symptomatic or asymptomatic and detected by&#xD;
             radiographic imaging). Participants with leptomeningeal disease and without cord&#xD;
             compression are allowed.&#xD;
&#xD;
         13. Have significant, uncontrolled, or active cardiovascular disease, specifically&#xD;
             including, but not restricted to the following:&#xD;
&#xD;
               -  Myocardial infarction within 6 months before randomization.&#xD;
&#xD;
               -  Unstable angina within 6 months before randomization.&#xD;
&#xD;
               -  New York Heart Association Class III or IV heart failure within 6 months before&#xD;
                  randomization.&#xD;
&#xD;
               -  History of clinically significant atrial arrhythmia (including clinically&#xD;
                  significant bradyarrhythmia), as determined by the treating physician.&#xD;
&#xD;
               -  Any history of clinically significant ventricular arrhythmia.&#xD;
&#xD;
         14. Had cerebrovascular accident or transient ischemic attack within 6 months before first&#xD;
             dose of study drug.&#xD;
&#xD;
         15. Have malabsorption syndrome or other gastrointestinal illness or condition that could&#xD;
             affect oral absorption of the study drug.&#xD;
&#xD;
         16. Have an ongoing or active infection, including but not limited to, the requirement for&#xD;
             intravenous antibiotics.&#xD;
&#xD;
         17. Have a known history of human immunodeficiency virus (HIV) infection. Testing is not&#xD;
             required in the absence of history.&#xD;
&#xD;
         18. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C&#xD;
             infection. Testing is not required in the absence of history.&#xD;
&#xD;
         19. Any serious medical condition or psychiatric illness that could, in the investigator's&#xD;
             opinion, potentially compromise patient safety or interfere with the completion of&#xD;
             treatment according to this protocol.&#xD;
&#xD;
         20. Have a known or suspected hypersensitivity to brigatinib or alectinib or their&#xD;
             excipients.&#xD;
&#xD;
         21. Life-threatening illness unrelated to cancer.&#xD;
&#xD;
         22. Female patients who are lactating and breastfeeding.&#xD;
&#xD;
         23. Admission or evidence of illicit drug use, drug abuse, or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>+1-866-835-2233</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>562-693-4477</phone>
      <email>mshum@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Merrill Shum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Cancer and Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>706-353-2990</phone>
      <email>ctpn@universitycancer.com</email>
    </contact>
    <investigator>
      <last_name>Petros Nikolinakos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology - Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>518-262-6696</phone>
      <email>makenzi.evangelist@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Makenzi Evangelist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>703-280-5390</phone>
      <email>alexander.spira@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Para la Atencion Integral del Paciente Oncologico</name>
      <address>
        <city>San Miguel De Tucuman</city>
        <state>Tucuman</state>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+5403814305518</phone>
      <email>fpalazzo98@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Felipe Palazzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanatorio Duarte Quiros</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+5403514891398</phone>
      <email>npilnik@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Norma Pilnik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Riojano Integral</name>
      <address>
        <city>La Rioja</city>
        <zip>F5300COE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+543804693919</phone>
      <email>dlkaen@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Diego Kaen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt Am Worthersee</name>
      <address>
        <city>Klagenfurt am Worthersee</city>
        <state>Carinthia</state>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>0043 463 538 25500</phone>
      <email>markus.rauter@lkh-klu.at</email>
    </contact>
    <investigator>
      <last_name>Markus Rauter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>902-473-8317</phone>
      <email>wojciech.morzycki@cdha.nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Wojciech Morzycki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>416-946-4501</phone>
      <email>geoffrey.liu@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica Bradford Hill</name>
      <address>
        <city>Recoleta</city>
        <state>Santiago</state>
        <zip>76894</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34917277535</phone>
      <email>mburotto@bradfordhill.cl</email>
    </contact>
    <investigator>
      <last_name>Mauricio Burotto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chest Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+86 136 5139 2121</phone>
      <email>liuzhe1968@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Zhe Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital - East</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8613911235467</phone>
      <email>mengzhaowang@sina.com</email>
    </contact>
    <investigator>
      <last_name>Mengzhao Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital/Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8613701224460</phone>
      <email>fangjian5555@yeah.net</email>
    </contact>
    <investigator>
      <last_name>Jian Fang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 307th Hospital of Chinese Peoples Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+86 136 8118 7500</phone>
      <email>liuxiaoqing@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaoqing Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8613521469355</phone>
      <email>ohjerry@163.com</email>
    </contact>
    <investigator>
      <last_name>Jun Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8613802777270</phone>
      <email>drjianxing.he@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jianxing He</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Harbin Medical University - The 3rd Affiliated Hospital of HMU</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+86 13633668886</phone>
      <email>chengongyan@163.com</email>
    </contact>
    <investigator>
      <last_name>Gongyan Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+86013938252350</phone>
      <email>zhaoyq657@163.com</email>
    </contact>
    <investigator>
      <last_name>Yan-Qiu Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin Provincial Cancer Hospital (Changchun Cancer Hospital)</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>13000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+86 18643112151</phone>
      <email>chengying@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Ying Cheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>020000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <email>xhwu2011@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Xianghua Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>13601813062</phone>
      <email>shun.lu@me.com</email>
    </contact>
    <investigator>
      <last_name>Shun Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+86 18622221232</phone>
      <email>dingzhih72@163.com</email>
    </contact>
    <investigator>
      <last_name>Dingzhi Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+86 137 5088 1678</phone>
      <email>zyp352@163.com</email>
    </contact>
    <investigator>
      <last_name>Yiping Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>31000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+86 135 0571 9970</phone>
      <email>drzjy@163.com</email>
    </contact>
    <investigator>
      <last_name>Jian-Ying Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Opca bolnica Dubrovnik</name>
      <address>
        <city>Dubrovnik</city>
        <state>Dubrovnik-Neretva</state>
        <zip>20 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+38520431692</phone>
      <email>zvrbica@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Zarko Vrbica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Pula</name>
      <address>
        <city>Pula</city>
        <zip>52100</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+38598335797</phone>
      <email>dtrivanovic@obpula.hr</email>
    </contact>
    <investigator>
      <last_name>Dragan Trivanovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Sestre milosrdnice</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+38513787421</phone>
      <email>jasna.radic@kbcsm.hr</email>
    </contact>
    <investigator>
      <last_name>Jasna Radic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika za Pulmologiju</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+38512385218</phone>
      <email>miroslav.samarzija@zg.htnet.hr</email>
    </contact>
    <investigator>
      <last_name>Miroslav Samarzija</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <state>Aquitaine</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33557656338</phone>
      <email>remi.veillon@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Remi Veillon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Creteil</name>
      <address>
        <city>Creteil</city>
        <state>Ile-de-france</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33157022057</phone>
      <email>christos.chouaid@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Christos Chouaid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <state>Ile-de-france</state>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33146255963</phone>
      <email>ac.metivier@hopital-foch.com</email>
    </contact>
    <investigator>
      <last_name>Anne-Cecile Metivier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif cedex</city>
        <state>Ile-de-france</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33142114322</phone>
      <email>david.planchard@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>David Planchard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse- Hopital Larrey</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <state>Midi-pyrenees</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33567771818</phone>
      <email>mazieres.j@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Julien Mazieres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans</name>
      <address>
        <city>Le Mans Cedex 9</city>
        <state>PAYS DE LA Loire</state>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33243434345</phone>
      <email>omolinier@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Molinier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Toulon - La Seyne Sur Mer</name>
      <address>
        <city>Toulon</city>
        <state>Provence Alpes COTE D'azur</state>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33494145870</phone>
      <email>clarisse.audigier-valette@ch-toulon.fr</email>
    </contact>
    <investigator>
      <last_name>Clarisse Audigier-Valette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Albert Michallon</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <state>Rhone-alpes</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33476768708</phone>
      <email>dmoro-sibilot@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Denis Moro-Sibilot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-wuerttemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4962213960</phone>
      <email>michael.thomas@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Michael Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken Munchen-Gauting</name>
      <address>
        <city>Gauting</city>
        <state>Bayern</state>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+4989857911000</phone>
      <email>n.reinmuth@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Niels Reinmuth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Kempten-Oberallgau</name>
      <address>
        <city>Immenstadt</city>
        <state>Bayern</state>
        <zip>87509</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+498323910808968</phone>
      <email>christian.schumann@kv-keoa.de</email>
    </contact>
    <investigator>
      <last_name>Christian Schumann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Athens Attikon</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302105835026</phone>
      <email>akoumari@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Anna Koumarianou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iaso General Hospital</name>
      <address>
        <city>Cholargos</city>
        <state>Attica</state>
        <zip>15562</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302106502639</phone>
      <email>georgouliasv@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vassilis Georgoulias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Oncology Hospital of Kifisia Oi Agioi Anargiroi</name>
      <address>
        <city>Nea Kifisia</city>
        <state>Attica</state>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302103501273</phone>
      <email>anvisvikis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anastassios Visvikis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Interbalkan Medical Center of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <state>Macedonia</state>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302310400368</phone>
      <email>bakasofia@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Sofia Baka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302413502124</phone>
      <email>thankotsakis@uth.gr</email>
    </contact>
    <investigator>
      <last_name>Athanasios Kotsakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sotiria General Hospital for Respiratory Diseases of Attica</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302107700220</phone>
      <email>ksyrigos.trials@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Konstantinos Syrigos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital</name>
      <address>
        <city>Chai Wan</city>
        <state>Eastern District</state>
        <zip>999077</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+85225956111</phone>
      <email>yeungmwr@ha.org.hk</email>
    </contact>
    <investigator>
      <last_name>Mei Wan Yeung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humanity and Health Research Centre</name>
      <address>
        <city>Central</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+85221161167</phone>
      <email>jane.chan@hnhmgl.com</email>
    </contact>
    <investigator>
      <last_name>Jane Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>00852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+85222554349</phone>
      <email>jhocm@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Chung-Man, James Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+85228554698</phone>
      <email>vhflee@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Ho Fun, Victor Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hong Kong United Oncology Centre</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+85223868002</phone>
      <email>ycli@hkuoc.hk</email>
    </contact>
    <investigator>
      <last_name>Yu-Chung, Jacky Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+85229902802</phone>
      <email>ackcheng@ha.org.hk</email>
    </contact>
    <investigator>
      <last_name>Chi Kin, Ashley Cheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>Forli-cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+39543739100</phone>
      <email>angelo.delmonte@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Angelo Delmonte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico di Aviano</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390434659294</phone>
      <email>abearz@cro.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Bearz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+39512142204</phone>
      <email>andrea.ardizzoni@aosp.bo.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Ardizzoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390105600665</phone>
      <email>carlo.genova1985@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carlo Genova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Universitario San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390226437626</phone>
      <email>gregorc.vanesa@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Vanesa Gregorc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390815903631</phone>
      <email>a.morabito@istitutotumori.na.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Morabito</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+39544286220</phone>
      <email>manolo.darcangelo@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Manolo D'Arcangelo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungcheongbuk-do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82432696015</phone>
      <email>kihlee@chungbuk.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Ki Hyeong Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82319201154</phone>
      <email>jymama@ncc.re.kr</email>
    </contact>
    <investigator>
      <last_name>Ji Youn Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <state>Gyeonggi-do</state>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82324608901</phone>
      <email>ekcho@gilhospital.com</email>
    </contact>
    <investigator>
      <last_name>Eun Kyung Cho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea St. Vincent's Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82312497114</phone>
      <email>shimby@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Byoung-Yong Shim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82312195989</phone>
      <email>leehw@ajou.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hyun Woo Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <state>Gyeongsangnam-do</state>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82522508832</phone>
      <email>yjmin@uuh.ulsan.kr</email>
    </contact>
    <investigator>
      <last_name>Young-Joo Min</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8229206724</phone>
      <email>yj_choi@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yoon Ji Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82220722995</phone>
      <email>kimdw@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dong-Wan Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+82234103438</phone>
      <email>silkahn@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Myung-Ju Ahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea - Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8225901081</phone>
      <email>oncologykang@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jin-Hyoung Kang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medica Sur</name>
      <address>
        <city>Ciudad de Mexico</city>
        <state>Cdmx</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+5529091366</phone>
      <email>cidjeronimo@yahoo.com.mx</email>
    </contact>
    <investigator>
      <last_name>Jeronimo Rodriguez Cid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Medica Aguascalientes</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20116</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+524499949458</phone>
      <email>salvadorperez.ags@osmomexico.com</email>
    </contact>
    <investigator>
      <last_name>Jesus Elvis Cabrera Luviano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Prof. Dr. Ion Chiricu</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+40745646368</phone>
      <email>tudor_ciuleanu@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Tudor-Eliade Ciuleanu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncocenter- Oncologie Clinic</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300166</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+400256221553</phone>
      <email>roxana.scheusan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Roxana Ioana Scheusan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucaresti</name>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+400212271001</phone>
      <email>auralexandru@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Aurelia Alexandru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrul de oncologie Euroclinic</name>
      <address>
        <city>Iasi</city>
        <zip>700106</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+40746110096</phone>
      <email>cvolovat@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Constantin Volovat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare Arkhangelsk Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Arkhangelsk</city>
        <state>Arkhangelr</state>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+78182276501</phone>
      <email>sm_nechaev@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Marina Nechaeva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Euromedservice</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Saint Petersburg</state>
        <zip>196603</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>79219044232</phone>
      <email>ninamosina@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Nina Mosina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg Clinical Scientific and Practical Center of Specialized Types of Medical Aid</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Saint Petersburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+79214399506</phone>
      <email>moiseenkofv@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fedor Moiseenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ultra Sound Diagnostic 4D</name>
      <address>
        <city>Pyatigorsk</city>
        <state>Stavropol</state>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+79197526202</phone>
      <email>dashavita@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Daria Saenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irkutsk Regional Oncology Center</name>
      <address>
        <city>Irkutsk</city>
        <zip>664035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+79148990254</phone>
      <email>dyuyu558@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Denis Yurevich Yukalchuk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin Russian Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+74993249850</phone>
      <email>evreutova@rambler.ru</email>
    </contact>
    <investigator>
      <last_name>Elena Reutova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VitaMed</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>79857695758</phone>
      <email>podd-elena@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Elena Poddubskaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budget Institution National Medical Research Center of Radiology of the Ministry of Heal</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+79262110975</phone>
      <email>fedenko@eesg.ru</email>
    </contact>
    <investigator>
      <last_name>Alexander Fedenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moscow City Oncology Hospital Number 62</name>
      <address>
        <city>Moscow</city>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+74955610100</phone>
      <email>sdaniel@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Daniil Stroyakovskiy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Omsk Regional Clinical Oncologic Dispensary</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+7 9136 882 778</phone>
      <email>mvdvorkin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mikhail Dvorkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Clinical Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>78125923560</phone>
      <email>alexander_luft@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Alexander Luft</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center of Palliative Medicine - Devita</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197343</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+79811957915</phone>
      <email>orloff-sv@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Sergey Orlov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Healthcare Institution Municipal Clinical Oncology Dispensary</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+79111019156</phone>
      <email>spboncologycenter@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Rashida Orlova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34934978925</phone>
      <email>mmoran@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Teresa Moran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrera - Materno Infantil</name>
      <address>
        <city>A Coruna</city>
        <state>LA Coruna</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34981178353</phone>
      <email>maria.rosario.garcia.campelo@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Maria Rosario Garcia Campelo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34934894375</phone>
      <email>efelip@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Enriqueta Felip Font</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34932275400</phone>
      <email>nreguart@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Noemi Reguart Aransay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34917567800</phone>
      <email>antonio.calles@live.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Calles Blanco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34913369159</phone>
      <email>pilargarridol@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pilar Garrido</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+349133030007552</phone>
      <email>jgonzalezl.hcsc@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Jose Luis Gonzalez-Larriba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34914692313</phone>
      <email>sponceaix@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Santiago Ponce Aix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34917277535</phone>
      <email>javier.decastro@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Javier de Castro Carpeno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34952390400</phone>
      <email>ensayosch@yahoo.es; manuelcobodols@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Cobo Dols</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34619848974</phone>
      <email>clara.lucia@grupsagessa.com</email>
    </contact>
    <investigator>
      <last_name>Clara Lucia Gozalvez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34629550590</phone>
      <email>dvicentebaz@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>David Vicente Baz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset - Solna</name>
      <address>
        <city>Solna</city>
        <state>Stockholm</state>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+46851774300</phone>
      <email>signe.friesland@sll.se</email>
    </contact>
    <investigator>
      <last_name>Signe Friesland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala Akademiska Sjukhus</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+46186110000</phone>
      <email>kristina.lamberg.lundstrom@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Kristina Lamberg-Lundstrom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua City</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+886-4-7238595 ext 7791</phone>
      <email>112364@cch.org.tw</email>
    </contact>
    <investigator>
      <last_name>Sheng-Hao Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hualien Tzu Chi Hospital</name>
      <address>
        <city>Hualien City</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8863856182512208</phone>
      <email>tfwang@tzuchi.com.tw</email>
    </contact>
    <investigator>
      <last_name>Tso-Fu Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+88673121101 #5651</phone>
      <email>jyhung@kmu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Jen-Yu Hung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chi Mei Hospital Liouying</name>
      <address>
        <city>Tainan City</city>
        <zip>73657</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+886 6-6226999 #72006</phone>
      <email>cjt@mail.chimei.org.tw</email>
    </contact>
    <investigator>
      <last_name>Chao-Jung Tsao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+886623535353120</phone>
      <email>sunnysu@mail.ncku.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Wu-Chou Su</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+88622312345667511</phone>
      <email>chihyang@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>James Chih-Hsin Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital Linkou Branch</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+886 5-362-1000</phone>
      <email>yang1946@adm.cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Cheng-Ta Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <state>Bangkok Metropolis</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+6622564533</phone>
      <email>vsmdcu40@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Virote Sriuranpong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <state>Bangkok Metropolis</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+6626404074</phone>
      <email>naiyarat_p@yahoo.co.th</email>
    </contact>
    <investigator>
      <last_name>Naiyarat Prasongsook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+66896575060</phone>
      <email>spatrapi@medicine.psu.ac.th</email>
    </contact>
    <investigator>
      <last_name>Patrapim Sunpaweravong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5f6b601c4db2bf003ab493af</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

